Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9ULH0
UPID:
KDIS_HUMAN
Alternative names:
Ankyrin repeat-rich membrane-spanning protein
Alternative UPACC:
Q9ULH0; A1L4N4; Q4VC08; Q6MZU2; Q9H889; Q9H9E4; Q9NT37; Q9UF42
Background:
The Kinase D-interacting substrate of 220 kDa, also known as an Ankyrin repeat-rich membrane-spanning protein, plays a pivotal role in neurotrophin signaling pathways. It promotes sustained MAP-kinase signaling, facilitates Rap1-dependent ERK activation, and is involved in neuronal outgrowth and regeneration. Its interaction with SNTA1 enhances JAK/STAT activation in response to EPHA4, underscoring its significance in postsynaptic signal transduction.
Therapeutic significance:
Given its involvement in diseases such as Spastic paraplegia, intellectual disability, nystagmus, and obesity, and Ventriculomegaly and arthrogryposis, understanding the role of the Kinase D-interacting substrate of 220 kDa could open doors to potential therapeutic strategies. Its regulatory role in apoptosis and neurotrophin-mediated neuronal pathways highlights its potential as a target in neurodegenerative diseases and developmental disorders.